血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察

史大卓; 李静; 马晓昌; 张群豪; 毛节明; 陈明哲; 陈可冀

doi:10.13288/j.11-2166/r.1997.01.016

您当前的位置：

首页 >

文章列表页 >

血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察

更新时间：2021-11-20

- 血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察
- Clinical Observation on Prevention of Restenosis in Cases with Coronary Heart Disease after Percutaneous Transluminal Coronary Angioplasty with Concentrated Xuefu Zhuyu Pill
- 中医杂志 1997年第1期页码：27-29
- 作者机构：
  
  1. 中国中医研究院西苑医院
  2. 北京医科大学第三临床医学院
  3. 中国中医研究院西苑医院北京海淀区西苑,100091
- 作者简介：
- 基金信息：
  
  国家中医药管理局“八·五”攻关课题
- DOI：10.13288/j.11-2166/r.1997.01.016
  中图分类号： R259.4
- 纸质出版：1997
- 稿件说明：
移动端阅览
[1]史大卓,李静,马晓昌,张群豪,毛节明,陈明哲,陈可冀.血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察[J].中医杂志,1997(01):27-29+4.

Clinical Observation on Prevention of Restenosis in Cases with Coronary Heart Disease after Percutaneous Transluminal Coronary Angioplasty with Concentrated Xuefu Zhuyu Pill[J]. Journal of Traditional Chinese Medicine1997, (1): 27-29.
[1]史大卓,李静,马晓昌,张群豪,毛节明,陈明哲,陈可冀.血府逐瘀浓缩丸预防冠心病病人经皮冠状动脉腔内成形术后再狭窄的临床观察[J].中医杂志,1997(01):27-29+4. DOI： 10.13288/j.11-2166/r.1997.01.016.

Clinical Observation on Prevention of Restenosis in Cases with Coronary Heart Disease after Percutaneous Transluminal Coronary Angioplasty with Concentrated Xuefu Zhuyu Pill[J]. Journal of Traditional Chinese Medicine1997, (1): 27-29. DOI： 10.13288/j.11-2166/r.1997.01.016.

摘要

选择经皮冠状动脉腔内成形术（PTCA）成功的冠心病患者

观察血府逐瘀浓缩丸对PTCA后再狭窄的预防作用。结果表明:西药常规治疗组复发心绞痛15例（15/38）

其中12例重复冠状动脉造影证实有11例再狭窄形成

另3例心电图活动平板复查示相关导联阳性

治疗前后血瘀证候积分值无明显变化（P>0.05）;加血府逐瘀浓缩丸组6例复发心绞痛（6/35）

心绞痛复发率显著低于西药常规治疗组（P<0.01）

其中5例重复冠状动脉造影复查证实有4例再狭窄形成

4例无心绞痛复发者重复冠状动脉造影证实无再狭窄形成

治疗后血瘀证候积分值比治疗前明显下降（P<0.01）。PTCA后心绞痛复发与“血瘀证”关系的分析发现

复发心绞痛患者血瘀证候积分值显著高于未复发心绞痛患者。血府逐瘀浓缩丸可改善PTCA患者的血瘀症状

对预防PTCA后再狭窄有一定的作用。

Abstract

Cases with coronary heart disease after successful PTCA were selected for observation of the preventive’ action of CXZP on restenosis of the vessel. Results revealed that （1） In the western medicine group 15 cases experienced recurrent angina pectoris. Among them

12 cases received repeated angiography

11 of them were confirmed to have restenosis while the 3 other cases were positive in ECG exercise treadmill test. No obvious changes were observed in stasis integration before and after treatment （P<0. 05）. （2） Only six cases had recurrent angina in the group with CXZP

markedly lower than that of the control group （P<0. 01） . Of them

4 cases were confirmed to have restenosis

where as the 4 cases without angina were confirmed to have no restenosis and the stasisintegration was markedly lowered than that before treatment （ P< 0. 01）. Analysis on the relation between recurrent angina and "blood stasissyndrome" after PTCA revealed that the stasis integration in recurrent group was markedly higher than that in nonrecurrent group

demonstrating that CXZP can distinctively improve the stasis symptoms and yield certain action on the prevention of restenosis in PTCA.

关键词

Keywords

references

查看原文

浏览量

263

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

调气定神法刍议

基于多模态大模型中医大数据平台的多中心社区获得性肺炎真实世界队列的构建与应用

通便汤对慢传输型便秘模型大鼠结肠组织VAPB-PTPIP51复合物及Cajal间质细胞自噬的影响

苇石清金方治疗成人社区获得性肺炎痰热壅肺证的真实世界疗效及经济学评价——一项多中心回顾性队列研究

“欲食”“能食”“喜食”之“问食”三要的内涵与应用